Clinical Trials Browser

Phase 2 × Leukemia, Myeloid, Acute × pembrolizumab × Clear all

NCT04214249 2026-03-04

BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia

Phase 2 Active not recruiting

49 enrolled 32 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02768792 2024-09-25

High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML

Phase 2 Completed

38 enrolled 14 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02771197 2023-09-28

Lymphodepletion and Anti-PD-1 Blockade to Reduce Relapse in AML Patient Not Eligible for Transplant

Phase 2 Completed

20 enrolled 9 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02845297 2023-03-09

Study of Azacitidine in Combination With Pembrolizumab in R/R AML Patients and in Newly Diagnosed Older Patients

Phase 2 Completed

67 enrolled 10 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT02708641 2021-08-10

A Phase II Study of Pembrolizumab as Post-Remission Treatment of Patients ≥ 60 With AML

Phase 2 Completed

12 enrolled 13 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute